Table 4.
KIR/ligand combinations in melanoma patients and healthy controls
| KIR/ligand | Frequency | |
|---|---|---|
| Patients (n=50) | Controls (n=54) | |
| Inhibitory KIR | ||
| 2DL1+/L+ | 30 (60.0%) | 35 (64.8%) |
| 2DL1+/L- | 15 (30.0%) | 14 ( 25.9%) |
| 2DL1-/L+ | 3 (6.0%) | 3 (5.6%) |
| 2DL2 and/or 2DL3+/L+ | 44 (88.0%)* | 37 (68.5%) |
| 2DL2 and/or 2DL3+/L- | 6 (12.0%)** | 17 (31.5%) |
| 2DL2 and/or 2DL3-/L+ | 0 | 0 |
| 3DL1+/L+ | 24 (48.0%) | 33 (61.1%) |
| 3DL1+/L- | 21 (42.0%) | 16 (29.6%) |
| 3DL1-/L+ | 5 (10.0%) | 5 (9.3%) |
| Activating KIR | ||
| 2DS1+/L+ | 11 (22.0%) | 13 (24.1%) |
| 2DS1+/L- | 8 (16.0%) | 5 (9.2%) |
| 2DS1-/L+ | 21 (42.0%) | 24 (44.4%) |
| 2DS2+/L+ | 22 (44.0%) | 23 (42.6%) |
| 2DS2+/L- | 6 (12.0%) | 11 (20.0%) |
| 2DS2-/L+ | 19 (38.0%) | 14 (25.9%) |
*p=0.017; OR=2.80; 95% CI, 0.09–0.91; **p=0.017; OR=0.27; 95% CI, 0.09–0.91